EMEA-002544-PIP01-18-M01

Table of contents

Key facts

Invented name
Retsevmo
Active substance
Selpercatinib
Therapeutic area
Oncology
Decision number
P/0398/2021
PIP number
EMEA-002544-PIP01-18-M01
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate dosage form
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
Oral use
Contact for public enquiries
Eli Lilly and Company

E-mail: EU_paediatric@lilly.com
Tel: +44 (0)1344 382000

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating